EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost-utility analysis of 177Lu-PSMA-617 radioligand therapy in second-line and third-line treatment for metastatic castration-resistant prostate cancer (mCRPC) in Germany

Carolin Brinkmann iD, Richard P Baum, Tom Stargardt

European Journal of Nuclear Medicine and Molecular Imaging · 2025-10 · 52 (12) · 4377-4389

DOI: 10.1007/s00259-025-07317-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 08.05.2025. Verfasst von Carolin Brinkmann und 2 weiteren Autor:innen. Beteiligte Einrichtung: Universität Hamburg, Hamburg Center for Health Economics, Esplanade 36, 20354, Hamburg, Germany. carolin.brinkmann@uni-hamburg.de. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Cost-Benefit Analysis, Dipeptides, Heterocyclic Compounds, 1-Ring. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, International Centers for Precision Oncology, Universität Hamburg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate the cost-effectiveness of 177 Lu-PSMA-617 radioligand therapy (PRLT) in metastatic castration-resistant prostate cancer (mCRPC) in Germany by comparing (I) PRLT plus standard-of-care (SoC) versus SoC alone as third-line treatment and (II) PRLT versus second-line cabazitaxel chemotherapy.

Methods

Cohort state-transition models were developed with (I) four health states (treatment, stable after treatment, progression, death) and (II) six health states (treatment, stable after treatment, third-line treatment after progression, stable after third-line treatment, next progression, death). Transition probabilities were derived from the VISION and TheraP trials, and quality-of-life data from the VISION and CARD trials. Costs were derived from statutory health insurance claims data (2019–2022). Models simulated a five-year horizon with one-month cycles, applying within-cycle correction and a 3% discount rate. Sensitivity analyses addressed uncertainty.

Results

For Model I, PRLT plus SoC compared to SoC incurred incremental costs of €27,200 per patient, with a gain of 0.39 quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER) of €69,418 per QALY gained. In Model II, PRLT plus SoC compared to cabazitaxel achieved incremental savings of €1,460 per patient and a QALY gain of 0.11, making it the dominant option.

Conclusion

Although Germany lacks an explicit willingness-to-pay threshold for interpreting the ICER of Model I, it falls within the range of other reimbursed cancer therapies. This suggests PRLT is cost-effective as second- or third-line treatment for mCRPC. Between 2019 and 2022, hospitals mainly used self-produced 177 Lu-PSMA-617, which was less costly than the product now commercially available, limiting the generalizability of our findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantCost-Benefit AnalysisDipeptidesHeterocyclic Compounds, 1-RingHumansMaleGermanyLutetiumNeoplasm MetastasisQuality-Adjusted Life YearsRadioisotopesProstate-Specific Antigen

Stichwörter der Autor:innen

177Lu-PSMA-617Cost effectivenessCost utilityMetastatic castration-resistant prostate cancerProstate cancerRadioligand therapy

Substanzen

DipeptidesHeterocyclic Compounds, 1-RingLutetiumPluvictoLutetium-177PSMA-617RadioisotopesProstate-Specific Antigen

Autor:innen und Institutionen

  • Universität Hamburg, Hamburg Center for Health Economics, Esplanade 36, 20354, Hamburg, Germany. carolin.brinkmann@uni-hamburg.de.
  • International Centers for Precision Oncology (ICPO), Wiesbaden, Germany.
  • CURANOSTICUM Wiesbaden-Frankfurt at DKD Helios Klinik, Wiesbaden, Germany.
  • Universität Hamburg, Hamburg Center for Health Economics, Esplanade 36, 20354, Hamburg, Germany.

ORCID-Profile: Carolin Brinkmann

Förderung

  • Deutsche Forschungsgemeinschaft
  • International Centers for Precision Oncology
  • Universität Hamburg

Zitieren

APA

Brinkmann, C., Baum, R. P., & Stargardt, T. (2025). Cost-utility analysis of 177Lu-PSMA-617 radioligand therapy in second-line and third-line treatment for metastatic castration-resistant prostate cancer (mCRPC) in Germany. European Journal of Nuclear Medicine and Molecular Imaging, 52(12), 4377-4389. https://doi.org/10.1007/s00259-025-07317-9

Vancouver

Brinkmann C, Baum RP, Stargardt T. Cost-utility analysis of 177Lu-PSMA-617 radioligand therapy in second-line and third-line treatment for metastatic castration-resistant prostate cancer (mCRPC) in Germany. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(12):4377-4389. doi:10.1007/s00259-025-07317-9

BibTeX
@article{Brinkmann2025,
  author = {Brinkmann, Carolin and Baum, Richard P and Stargardt, Tom},
  title = {Cost-utility analysis of 177Lu-PSMA-617 radioligand therapy in second-line and third-line treatment for metastatic castration-resistant prostate cancer (mCRPC) in Germany},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  volume = {52},
  number = {12},
  pages = {4377--4389},
  doi = {10.1007/s00259-025-07317-9}
}
Kostenlos starten →